NVAX FY 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.1B+64.7% YoY

Gross Profit

$1.1B93.7% margin

Operating Income

$563M50.1% margin

Net Income

$440M39.2% margin

EPS (Diluted)

$2.54

Cash Flow

Operating Cash Flow

-$245M

Free Cash Flow

-$250M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.3B

Stockholders' Equity

-$128M

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$682M	+64.7%
Gross Profit	$1.1B	$479M	+119.5%
Operating Income	$563M	-$249M	+326.3%
Net Income	$440M	-$187M	+334.8%